Tag Archives: Osanetant

Schizophrenia: Neurokinin Antagonists

One potential competitive advantage for the neurokinin antagonists over other schizophrenia drugs is their theoretical efficacy in the treatment of depression. In any one year, an estimated 20-40% of schizophrenia patients are vulnerable to a major depressive episode. As a result, any drug that treats this comorbidity in addition to psychotic symptoms would find a… Read More »

Schizophrenia: Serotonin-Dopamine Antagonists

Serotonin-dopamine antagonists, together with dopamine partial agonists, are considered atypical antipsychotics. serotonin-dopamine antagonists have been used for the treatment of schizophrenia since the early 1990s, and currently marketed serotonin-dopamine antagonists include Novartis’s clozapine (Clozaril/Leponex, generics), Janssen’s risperidone (Risperdal), Eli Lilly’s olanzapine (Zyprexa), AstraZeneca’s quetiapine (Seroquel), and Pfizer’s ziprasidone (Geodon/Zeldox). TABLE . Emerging Therapies in Development… Read More »

Minor Depression: Neurokinin Antagonists

Overview A new neurotransmitter system being targeted for the treatment of minor depression is a family of three related peptides known as neurokinins; the most interesting of these is the NK substance P. Two more neurokinins, not extensively investigated in the area of depression, are NK A and NK B. The specific receptor subtypes that… Read More »